Turn Therapeutics (NASDAQ:TTRX) Stock Dropped to Sell by Wall Street Zen

Wall Street Zen lowered shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a research note released on Sunday,Wall Street Zen reports.

Several other equities analysts also recently issued reports on TTRX. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. WBB Securities reiterated a “sell” rating and issued a $10.00 target price on shares of Turn Therapeutics in a research note on Monday, September 14th. Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Finally, Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Turn Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Stock Performance

NASDAQ:TTRX opened at $10.57 on Friday. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $16.45. The stock has a market cap of $314.88 million and a P/E ratio of -36.45. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a 50-day simple moving average of $11.60 and a 200-day simple moving average of $7.93.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. As a group, analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SteelPeak Wealth LLC raised its stake in shares of Turn Therapeutics by 0.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after buying an additional 1,819 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in shares of Turn Therapeutics in the 3rd quarter valued at approximately $40,000. Bank of America Corp DE purchased a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $103,000. Jefferies Financial Group Inc. purchased a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $119,000. Finally, DDFG Inc boosted its stake in shares of Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after buying an additional 18,246 shares in the last quarter.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.